Authors' recommendations: Pancreatic cancer is a very aggressive cancer that is difficult to treat. It often does not cause any symptoms in its early stages, so it is often not detected and diagnosed until the cancer has spread to other nearby organs or to other parts of the body (advanced cancer). Once pancreatic cancer has reached an advanced stage, it cannot be cured. Reolysin is a new drug for the treatment of advanced stage cancer that is delivered straight into the bloodstream via a drip. It is given alongside the usual chemotherapy drugs used to treat pancreatic cancer. Some studies have suggested Reolysin may be helpful as a first treatment for this disease, and more studies are now aiming to show how well it works and that it is safe to use. If Reolysin is licensed for use in the UK, it could be a new treatment option for advanced pancreatic cancer that could improve survival.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/reolysin-for-advanced-or-metastatic-pancreatic-cancer-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)